VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults
Aesthetic Surgery Journal · 2025
DOI: 10.1093/asj/sjaf033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Yun Xie und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermal Fillers, Cosmetic Techniques, Hyaluronic Acid, Lidocaine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, AbbVie company.
Abstract (Originalsprache)
Background
Individuals with chin retrusion may seek chin and lower jawline aesthetic enhancement.
Objectives
To evaluate VYC-25L (Juvéderm Volux XC; Allergan Aesthetics, an AbbVie company), a lidocaine-containing injectable hyaluronic acid dermal filler, for chin retrusion correction.
Methods
In this prospective, Phase 3, multicenter study (NCT04559984), Chinese adults with moderate-to-severe chin retrusion on the China (Allergan) Chin Retrusion Scale (CACRS) and glabella–subnasale–pogonion (G–Sn–Pog) angle <172.5° were randomized 2:1 to VYC-25L (treatment plus optional touch-up 4 weeks later) or no treatment (control). The primary endpoint was change from baseline (CFB) in G–Sn–Pog angle at Week 24. Secondary endpoints included CACRS response (≥1-point improvement), Global Aesthetic Improvement Scale (GAIS) response (improved/much improved), and FACE-Q Satisfaction with Chin score. Procedural pain was rated (0 = none to 10 = worst imaginable); injection-site responses (ISRs) were recorded daily for ≤28 days.
Results
The mean age of the patient (VYC-25L, n = 97; control, n = 51) was 31.2 years (range, 20-52 years). Mean CFB in G–Sn–Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control; between-group difference, 3.08° [P < .0001]); improvement was maintained to Week 52. At Week 24, VYC-25L achieved higher responses vs control for CACRS (78.7% vs 18.8%, respectively; rate difference, 60.0%; P < .0001) and GAIS (92.6% vs 4.2%, respectively; rate difference, 88.4%; P < .0001); mean overall FACE-Q Satisfaction with Chin score was 70.4 vs 34.9, respectively. Mean (standard deviation) procedural pain was 2.6 (1.6); most ISRs were mild (41.8%) or moderate (50.0%) in severity.
Conclusions
In Chinese adults, VYC-25L safely and effectively corrected chin retrusion for at least 1 year. Level of Evidence: 2 (Therapeutic)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Förderung
- Allergan Aesthetics
- AbbVie company
Zitieren
APA
Xie, Y., Li, Q., Zhao, H., Qi, Z., Sun, J., Tan, Q., Li, D., Hu, Z., Liu, Z., & Chawla, S. (2025). VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf033
Vancouver
Xie Y, Li Q, Zhao H, Qi Z, Sun J, Tan Q, et al. VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf033
BibTeX
@article{Xie2025,
author = {Xie, Yun and Li, Qingfeng and Zhao, Hongyi and Qi, Zuoliang and Sun, Jiaming and Tan, Qian and Li, Dong and Hu, Zhiqi and Liu, Ziyang and Chawla, Smita},
title = {VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults},
journal = {Aesthetic Surgery Journal},
year = {2025},
doi = {10.1093/asj/sjaf033}
}
EUVIMED